9 views 0 likes

StayCurrentMD

GCMD Space · View profile →

Soft Tissue Sarcoma Rapid Fire: Update Course 2015

Video Published 2019-01-11 Updated 2026-02-12

Timestops (5)

Rhabdomyosarcoma Prognosis by Site

Clinical Grouping and Surgical Goals

Case Example: Sentinel Node Mapping

Non-Rhabdo Sarcomas: Tumor Grade Focus

Surgical Strategy by Tumor Size

Topic Overview

A surgical update on pediatric soft tissue sarcomas covering rhabdomyosarcoma and non-rhabdomyosarcoma tumors. The speaker emphasizes that staging and grouping determine prognosis, with group 1 and 2 patients having excellent outcomes while group 3 patients fare worse. Key updates include mandatory sentinel lymph node biopsy for trunk and extremity rhabdomyosarcomas (with radiation but no completion dissection if positive), and the critical importance of histologic grade in non-rhabdo tumors—low-grade tumors can be cured with surgery alone if margins are negative, while high-grade tumors require multimodal therapy. The speaker stresses that tumor size thresholds should be adjusted for patient age, with 3 cm being more appropriate than 5 cm in toddlers.

Key Takeaways

Sentinel lymph node biopsy now mandatory for trunk/extremity rhabdo; positive nodes get radiation, not completion dissection (3:18)
Low-grade non-rhabdo sarcomas with negative margins need only surgery—no chemo or radiation required for cure (5:21)
Histologic grade now critical in non-rhabdo tumors: determines whether multimodal therapy is needed beyond resection (4:54)
Use 3 cm cutoff (not 5 cm) for resection vs biopsy decision in toddlers—adjust size thresholds for patient age (6:54)
Chemoinsensitive sarcomas (alveolar soft part, malignant epithelioid, clear cell) are all high-grade; treat with surgery + radiation (6:28)

Inside this episode

Kai, the Library's AI content creator, listened to this episode and mapped who's speaking, the chapters, key claims, and cases. Every item links to the exact moment in the recording.

AI-enriched

Who's speaking

Andrea — guest
Speaker 2 — host
Speaker 3

Chapters

0:00Rhabdomyosarcoma Staging and Grouping — Introduction to soft tissue sarcomas with focus on rhabdomyosarcoma staging by site (favorable vs unfavorable) and surgical grouping (1-3). Prognosis varies by site with orbital tumors having best survival and abdominal/pelvic/retroperitoneal having worst. Group 1 and 2 patients show excellent prognosis while group 3 patients do more poorly.
2:06Rhabdomyosarcoma Case Examples and Sentinel Node Biopsy — Two case presentations of extremity rhabdomyosarcoma demonstrating proper management including sentinel lymph node biopsy. First case: 5-year-old with 4 cm forearm mass, resected elsewhere with positive margins, underwent re-excision and sentinel node biopsy (negative). Second case: 2-year-old with positive sentinel nodes requiring axillary radiation. Emphasizes that sentinel lymph node biopsy is now required for trunk and extremity rhabdomyosarcoma.
4:31Non-Rhabdomyosarcoma Soft Tissue Sarcomas — Updates on non-rhabdo sarcomas emphasizing histologic grade as critical factor. Low-grade tumors require only resection and observation (radiation only if positive margins). High-grade unresectable tumors now receive both preoperative chemotherapy and radiation. Chemosensitive tumors (synovial, undifferentiated) versus chemoinsensitive tumors (alveolar soft part, malignant epithelioid, clear cell) require different treatment approaches.
6:54Summary and Q&A — Key takeaways including age-adjusted size thresholds (3 cm in toddlers vs 5 cm in older children), mandatory sentinel node biopsy for clinically negative nodes, importance of tumor grade for non-rhabdo tumors, and aggressive surgical approach for chemoinsensitive tumors. Brief Q&A addressing acceptability of core biopsies.

Key claims

0:00Half of soft tissue sarcomas are rhabdomyosarcomas and half are non-rhabdos — Andrea
0:25Prognosis in rhabdomyosarcoma varies depending on site — Andrea
0:25Abdominal, pelvic, and retroperitoneal rhabdomyosarcomas have the worst survival — Andrea
0:25Orbital rhabdomyosarcomas have the best survival — Andrea
0:50Favorable sites (vaginal, paratesticular rhabdos) are stage 1 — Andrea
1:02Even small tumors in the extremity or abdomen can only achieve stage 2 at best — Andrea
1:14Surgical extent determines clinical group: group 1 if everything removed, group 2 if microscopic residual, group 3 if only biopsy performed — Andrea
1:30Group 1 and 2 patients have an excellent prognosis while group 3 patients do more poorly — Andrea
1:45Group assignment is a biologic determination, not a measure of surgical skill — Andrea
1:52Attempting to resect a large unresectable tumor with high morbidity will not improve patient outcome — Andrea
2:095 centimeters is the cutoff for low versus high-risk patients in soft tissue sarcoma — Andrea
3:18Sentinel lymph node biopsies are now required for all trunk and extremity rhabdomyosarcomas — Andrea
3:34In rhabdomyosarcoma, completion node dissection is not performed after positive sentinel nodes; radiation therapy is given instead — Andrea
4:3940 to 50% of biopsy nodes are positive in rhabdomyosarcoma — Andrea
4:39Clinically negative nodes may be positive on sentinel node biopsy — Andrea
4:39Positive lymph nodes have worse prognosis and require radiation therapy — Andrea
4:54Histological grade is now critical in non-rhabdo soft tissue sarcomas — Andrea
4:54Large tumors should be biopsied first and chemotherapy tried — Andrea
5:13Sarcomas have been identified as chemotherapy-sensitive or chemotherapy-insensitive, which changes treatment — Andrea
5:21Low-grade tumors require only resection and observation with no radiation or chemotherapy — Andrea
5:38Low-grade tumors with positive margins receive adjuvant radiation therapy — Andrea
5:52Unresectable tumors now receive both preoperative chemotherapy and radiation therapy (previously only chemotherapy was recommended) — Andrea
6:10Small tumors less than 5 centimeters should be resected with attempt at negative margins — Andrea
6:10Chemosensitive tumors include synovial and undifferentiated sarcomas — Andrea
6:28Chemoinsensitive tumors include alveolar soft part, malignant epithelioid, and clear cell sarcomas — Andrea
6:28All chemoinsensitive tumors are high-grade; none are low-grade — Andrea
6:28Surgery and radiation are the primary treatments for chemoinsensitive tumors — Andrea
6:54A 5 centimeter tumor in a child less than 3 years old is equivalent to a 3 centimeter tumor in bigger patients — Andrea
6:543 centimeters should be the cutoff for excision versus biopsy in toddlers rather than 5 centimeters — Andrea
7:15Sentinel lymph node biopsy should be performed if lymph nodes are clinically negative by imaging — Andrea
7:15Positive lymph nodes receive radiation to the lymph node basin without completion node dissection — Andrea
7:25Low-grade non-rhabdo tumors with negative margins can be cured with surgery alone without chemotherapy — Andrea
7:37Chemoinsensitive tumors require aggressive surgical extirpation — Andrea
8:10Core biopsies are acceptable if 3 or 4 good non-necrotic cores are obtained — Andrea
8:10Pathologist should check core biopsy samples before interventional radiologist finishes to ensure tissue is not all necrotic — Andrea

Cases discussed

2:065-year-old with 4 cm forearm alveolar rhabdomyosarcoma resected at outside hospital with positive margins
4:072-year-old with rhabdomyosarcoma who had excisional biopsy with positive margins and positive sentinel nodes

This episode was analyzed and enriched by Kai, the Library's AI content creator. Every item links to the moment it comes from — click a timestamp to listen in context.

Soft Tissue Sarcoma Management: When Biology Trumps Surgical Ambition

The episode's teaching points arranged as a structured lesson, building from the basics up to the finer points. Written by Kai from the episode transcript and reviewed before publishing.

For specialists · Teaching arc · AI-written, human-reviewed

Group assignment reflects tumor biology, not surgical prowess

The clinical group in rhabdomyosarcoma—group 1 for complete resection, group 2 for microscopic residual, group 3 for biopsy only—determines prognosis alongside stage 1:14 1:30. But attempting a high-morbidity resection to convert a group 3 tumor into group 2 accomplishes nothing 1:52. "This is basically a biologic determination. If there's a large tumor that a surgeon can't resect, it's gonna be a group 3, and you trying to resect that with a lot of morbidity is not going to make that patient's outcome any better" [q1]. The group reflects what the tumor allows, not what the surgeon achieves. A 4-centimeter mass in a five-year-old's forearm is enormous relative to the limb—biopsy first, then reassess after chemotherapy shrinks it to something resectable with negative margins 6:10.

Size thresholds scale with patient size

The standard 5-centimeter cutoff separating low-risk from high-risk soft tissue sarcomas does not account for body habitus 2:09. A 5-centimeter tumor in a child under three years is equivalent to a 3-centimeter tumor in larger patients 6:54. Use 3 centimeters as the threshold for excision versus biopsy in toddlers 6:54. This adjustment prevents attempting primary resection of tumors that are functionally unresectable given the anatomic constraints of a small child.

Sentinel node management diverges from melanoma protocols

Sentinel lymph node biopsy is now required for all trunk and extremity rhabdomyosarcomas 3:18. Forty to fifty percent of biopsied nodes are positive, and clinically negative nodes may harbor disease 4:39 4:39. But unlike melanoma, positive sentinel nodes in rhabdomyosarcoma do not trigger completion lymph node dissection—radiation to the nodal basin is the treatment 3:34 7:15. "The difference in rhabdo as far as the other diseases that we're used to, such as melanoma, is that you do not do a completion node dissection, you just get radiation therapy" [q3]. Positive nodes confer worse prognosis and mandate radiation, but the surgical response is limited to the sentinel procedure 4:39.

Histologic grade now drives non-rhabdo treatment decisions

"The histological grade is now critical" [q4]. Low-grade non-rhabdo sarcomas with negative margins can be cured with surgery alone—no chemotherapy, no radiation, only observation 5:21 7:25. Low-grade tumors with positive margins receive adjuvant radiation 5:38. This represents a shift from reflex multimodal therapy toward recognizing that grade, not just diagnosis, determines treatment intensity 4:54. High-grade tumors require chemotherapy and radiation; low-grade tumors may not. The pathology report must specify grade before treatment planning proceeds.

Chemosensitivity stratifies surgical aggressiveness

Non-rhabdo sarcomas now separate into chemosensitive (synovial, undifferentiated) and chemoinsensitive (alveolar soft part, malignant epithelioid, clear cell) subtypes 6:10 6:28. All chemoinsensitive tumors are high-grade 6:28. For chemosensitive tumors, neoadjuvant chemotherapy can convert an unresectable mass into something manageable. For chemoinsensitive tumors, surgery and radiation are the primary modalities—chemotherapy offers little 6:28 7:37. This distinction determines whether you biopsy a large tumor and wait for shrinkage or proceed directly to aggressive surgical extirpation. Unresectable high-grade tumors now receive both preoperative chemotherapy and radiation, not chemotherapy alone 5:52.

Core biopsy suffices if tissue quality is confirmed

Core biopsies are acceptable if three or four good non-necrotic cores are obtained 8:10. The pathologist must examine the cores before the interventional radiologist finishes to confirm adequate non-necrotic tissue 8:10. This intraoperative quality check prevents the need for repeat biopsy when the initial sample is all necrotic. The emphasis is on tissue adequacy for grading and subtype determination, not on biopsy technique.

The overarching principle: treatment intensity matches tumor biology. Surgical restraint when biology dictates group 3, aggressive resection when chemotherapy cannot help, and observation alone when grade permits—each decision rests on recognizing what the tumor is rather than what the surgeon wishes it were.

Takeaways from this story

Clinical group in rhabdo reflects tumor biology—high-morbidity resection to improve grouping does not improve outcome
Use 3 cm, not 5 cm, as the resection threshold in children under 3 years—size cutoffs must scale with patient size
Positive sentinel nodes in rhabdo get radiation to the basin, not completion dissection—protocol differs from melanoma
Low-grade non-rhabdo sarcomas with negative margins need only observation—no chemo, no radiation
Chemoinsensitive sarcomas (alveolar soft part, epithelioid, clear cell) require aggressive surgery—chemotherapy offers little

Keywords

rhabdomyosarcoma alveolar rhabdomyosarcoma orbital rhabdomyosarcoma vaginal rhabdomyosarcoma paratesticular rhabdomyosarcoma soft tissue sarcoma non-rhabdomyosarcoma soft tissue sarcoma synovial sarcoma undifferentiated sarcoma alveolar soft part sarcoma malignant epithelioid sarcoma clear cell sarcoma sentinel lymph node biopsy sentinel lymph node mapping re-excision

Hashtags

#PediatricSurgery #Rhabdomyosarcoma #SoftTissueSarcoma #SurgicalOncology

Transcript

OK, so these soft tissue sarcomas are quite rare and so we'll take this opportunity to give folks an update just on what's new as far as surgical therapies in these soft tissue sarcomas, and half of them are rhabdomyosarcomas, but the other half are the non-rhabdos, so we'll spend a couple of minutes on each one. So we're talking about a very, the very rare sarcomas, and the important thing to remember is that these and rhabdomyosarcoma. We'll talk about first, the prognosis varies depending on site and so the, the patients that we see the most often, of course, are the abdominal, pelvic, retroperineal ones, and those are the ones that have the worst survival over here under other and then the best survivors are the orbital r Rhabdomyosarcomas and because I know people don't deal with these every day, I'm gonna just very quickly go through how we stage them with uh favorable. Sites. So if you have a favorable site, this is basically vaginal rhabdos, persticular rhabdos. Those are stage 1 and stage 23, and 4 are unfavorable sites with various amounts of disease. But what I'd like you to remember is that, you know, we basically don't see a lot of stage 1 patients. So even if you have a small tumor in the extremity or the abdomen, the best that patient can do is a stage 2. A group, the grouping, it depends on the surgical extent. So you as a surgeon determine the clinical group. If you remove everything, it's a group 1. If you leave microscopic residual behind, it's a group two, and if you can't get it out and you just do a biopsy, it's a group 3. So the stage and the group combined are what determines how the patient's outcome is and as you can see in this Kaplan-Myer curve, the group 1 and 2 patients have an excellent prognosis, and the group 3 patients are the ones that do a little bit more poorly. I do want to emphasize here that this doesn't mean. That the, the good surgeons, quote unquote, they're ones that can get it down to group 2. This is basically a biologic determination. If there's a large tumor that a surgeon can't resect, it's gonna be a group 3, and you trying to resect that with a lot of morbidity is not going to make that patient's outcome any better. So first case, this is a 5 year old with a mass on the forearm. It's 4 centimeters in size, and as we know, 5 centimeters is the cutoff for sort of a low or a high-risk patient. So it's a 4 centimeter tumor in a 5 year old, uh, we're, we're gonna talk about this later, it's not for you to answer out loud, but just to think in your head whether you would resect it. This particular patient had their 4 centimeter tumor resected in an outside hospital. It turned out to be alveolar rhabdo. The margins were positive, uh, and of course the forearm of a 5 year old is gonna be quite small. Uh, the, on the CT scan, the axillary nodes were clinically negative, so they came to us and we did a re-incision and a sentinel lymph node biopsy, which none of the nodes were positive, and so they did not need radiation therapy to the axilla. So the, the, this is the same case and sort of the way we should be approaching it. And if you have a 5 year old with a 4 centimeter mass, even though it's less than 5 centimeters, we all know as pediatric surgeons that that's a huge mass in the forearm of a 5 year old. And to make an attempt to try to resect that is probably not gonna be worthwhile, and you should probably just do a biopsy and see what you have. But in addition, as far as updates are concerned, the one thing I want to emphasize with Rhabdo on this update is that now we are requiring sentinel lymph node biopsies for all of these patients. So if you have a patient with the trunk or extremities, rhabdomyosarcoma, you have to do a sentinel lymph node biopsy. Um, and once you do the sentinel lymph node biopsy, the, the difference in rhabdo as far as the other diseases that we're used to, such as melanoma, is that you do not do a completion node dissection, you just get radiation therapy. So back to this patient, so we do the sentinel lymph node biopsy, none of the nodes are positive, so no radiation therapy. Now, the, if since it's alveolar rhabdo, they will get chemo, they, they should get chemotherapy after you did the biopsy, and now this is, this is usually gonna be down to a 1 centimeter mass, it's very easy to resect with negative margins. The next case is a 2 year old where has an excisional biopsy, uh, again, the margins were positive, the surgeon knew, didn't know what it was and sort of knew that they would be positive and went back to do a re-excision, and that's the time of re-excision that you need to do your sentinel lymph node mapping. And in this case, the, the sentinel lymph nodes were positive and that patient received axillary radiation therapy and chemotherapy. So the lymphatic mapping is something I know we've all learned, but as far as Rhabdo, it's been one of those things that's been optional and now it's being required. So, 40 to 50% of the biopsy nodes are positive, the clinically negative nodes may also be positive, so that's why we're doing the sentinel node biopsy, and we know that positive nodes have a worse prognosis and require radiation therapy. So we're gonna switch to non-rhabdose soft tissue sarcoma, so the, the changes in non-rhabdos, and what I want you to remember is the histological grade is now critical. We know that large tumors, you should biopsy first and try chemotherapy, but the histologic grade is what you should be paying attention to and not just the diagnosis. And, and the other difference is that we've identified sarcomas that are chemotherapy, insensitive and sensitive, and that changes the treatment. So, I'm just gonna briefly want you to focus on this tumor grade part of this slide, which is the current recommended treatment for soft tissue sarcomas. If you have a low-grade tumor, all you're gonna do is resect that patient and they're only gonna get observed. There's no need for radiation or chemotherapy. If you resect a low-grade tumor and you have positive margins, they will get adjuvant radiation therapy. Uh, so this is something. That um we've shown, and I'm not gonna share all the data because of time reasons, but that is now the new recommended treatment. The other thing I want to point out here is if you have an unresectable tumor that's huge, that you want to treat that patient with preoperative radiation therapy, uh, and preoperative chemotherapy, but first, uh, we were first only recommending preoperative chemo, now we're recommending both chemo and radiation. So small tumors less than 5 centimeters, uh, go ahead and resect those, try to get a negative margin, and to know that the chemosensitivity tumor, the chemo sensitive tumors are the ones that you, if you can't resect, you'd be enthusiastic about giving chemotherapy first, that's the synovial and undifferentiated. The chemo insensitive, uh, tumors, sorry, that's a type I should say insensitive, are the alveolar soft part, the malignant epithelioid clear cell, anything else that's sort of other. Those are the ones that you as a surgeon, the radiation therapist really will be the primary treater of those uh disorders, and all of those are high grade, none of those are low-grade tumors. And then of course the high risk patients to get the uh preoperative radiation and chemotherapy. So when endowed biopsy, remember that the uh the Italians did a very nice study showing that a 5 centimeter tumor in a small child less than 3 years old is about the same as a 3 centimeter tumor in a in a in a. Bigger patients, so you really wanna think about more 3 centimeters as your cutoff for excision as opposed to 5 centimeters if you're dealing with a toddler. Always do a sentinel lymph node biopsy if clinically the lymph nodes are negative by imaging, and remember that they're gonna radiate the lymph node base and you do not have to do a completion node dissection. Find out what the grade of the tumor is if you're resecting a non-rhabdo tumor because those are the ones you can cure with surgery alone, uh, and if you have negative margins, those patients don't need chemotherapy. The chemo insensitive tumors are the ones that you wanna be very aggressive with surgically, uh, to try to extirpate, extirpate those as much as possible. Thank Perfect. And Andrea, thank you very much. And uh and, and there's a quick question. I think we're about a half an hour behind, so we're gonna move ahead. Does anyone have a quick comment or question? Core biopsy versus open experience. You hear that, Andrea? Oh, he asked about a core biopsy. Core biopsies are acceptable. Uh, you'll, you'll need to have your pathologist check the core before the interventional radiologist is finished to make sure that it's not all necrotic, but as long as you get 3 or 4 good cores that are not necrotic, those are acceptable. Very good. Any other?

Comments

Loading comments…